Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23315960 | 0.86 | OPRM1 (0.31) | OPRM1 | |
| SCHEMBL22663697 | 0.82 | USP2 (0.32) | — | |
| SCHEMBL22255130 | 0.80 | SLC22A1 (0.40) | SLC22A1CHRM2ACHESLC6A4OPRM1 | |
| SCHEMBL2344033 | 0.77 | HSD17B10 (0.36) | OPRM1 | |
| SCHEMBL7997017 | 0.75 | CETP (0.36) | — | |
| SCHEMBL25467291 | 0.75 | SLC22A1 (0.36) | SLC22A1CHRM2ACHESLC6A4OPRM1 | |
| SCHEMBL8179032 | 0.74 | OPRM1 (0.33) | CHRM2OPRM1 | |
| SCHEMBL23466099 | 0.74 | SLC22A1 (0.34) | SLC22A1CHRM2ACHESLC6A4OPRM1 | |
| Ammonia Solution, Strong SCHEMBL28128663 | 0.73 | CETP (0.35) | — | |
| SCHEMBL11227490 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105220-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | DENG XIAOHU | 2009-04-23 | — | — | US | disclosed |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105220-A1 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES | REN, AVPR1B, WNK1 | SLC22A1 4080/4885CHRM2 3102/4885ACHE 3650/4885 |
| US-20040259857-A1 | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | REN, AVPR1B, WNK1 | SLC22A1 4080/4885CHRM2 3102/4885ACHE 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.